Atypical antipsychotic use and risk of fracture in persons with Parkinsonism

Movement Disorders

Volumn 24, Issue 13, 2009, Pages 1941-1948

  Dore, David D ^a,b   Trivedi, Amal N ^b   Mor, Vincent ^b   Friedman, Joseph H ^c,d   Lapane, Kate L ^b,e  

^a i3 Drug Safety   (United States)

^b BROWN UNIVERSITY   (United States)

^c NeuroHealth   (United States)

^d BROWN UNIVERSITY   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Atypical antipsychotic; Fracture; Parkinsonism; Pharmacoepidemiology

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ANKLE FRACTURE; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG USE; FEMALE; FEMUR FRACTURE; FIBULA FRACTURE; FRACTURE; HUMAN; HUMERUS FRACTURE; MAJOR CLINICAL STUDY; MALE; PARKINSONISM; PRESCRIPTION; PRIORITY JOURNAL; RADIUS FRACTURE; RISK ASSESSMENT; TIBIA FRACTURE; ULNA FRACTURE; UNITED STATES;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DATABASES, FACTUAL; FEMALE; FRACTURES, BONE; HUMANS; LOGISTIC MODELS; MALE; MEDICAID; MIDDLE AGED; ODDS RATIO; PARKINSONIAN DISORDERS; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 70450161119     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22679     Document Type: Article

References (43)

1. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol 2005;252:1310-1315. (Pubitemid 41699019)
2. Kelsey JL, Prill MM, Keegan THM, Quesenberry CP, Jr, Sidney S. Risk factors for pelvis fracture in older persons. Am J Epidemiol 2005;162:879-886. (Pubitemid 41541372)
3. Bloem BR, Grimbergen YA, Cramer M, Willemsen M, Zwinderman AH. Prospective assessment of falls in Parkinson's disease. J Neurol 2001;248:950-958. (Pubitemid 36124720)
4. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003;60:387-392. (Pubitemid 36314364)
5. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300. (Pubitemid 38971129)
6. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. (Pubitemid 41345943)
7. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 2001;16:135-139. (Pubitemid 36041128)
8. Kurlan R, Cummings J, Raman R, Thal L, For the Alzheimer's Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 2007;68:1356-1363.
9. Breier A, Sutton VK, Feldman PD, et al. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445. (Pubitemid 35266735)
10. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
11. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004;184:503-508. (Pubitemid 38725710)
12. Ooi WL, Hossain M, Lipsitz LA. The association between orthostatic hypotension and recurrent falls in nursing home residents. Am J Med 2000;108:106-111. (Pubitemid 30064420)
13. Aizenberg D, Sigler M, Weizman A, Barak Y. Anticholinergic burden and the risk of falls among elderly psychiatric inpatients: a 4-year case-control study. Int Psychogeriatr 2002;14:307-310. (Pubitemid 35375545)
14. Liperoti R, Onder G, Lapane KL, et al. Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case-control study. J Clin Psychiatry 2007;68:929-934. (Pubitemid 47015494)
15. Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 2005;60:622-626.
16. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-1943. (Pubitemid 41464695)
17. Liperoti R, Pedone C, Lapane KL, Mor V, Bernabei R, Gambassi G. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005;165:2677-2682. (Pubitemid 41785068)
18. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-235.
19. Swarztrauber K, Dawn-Peters J. Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data. Mov Disord 2005;20:964-970. (Pubitemid 41419511)
20. Wysowski DK, Baum C. The validity of Medicaid diagnoses of hip fracture. Am J Public Health 1993;83:770. (Pubitemid 23143018)
21. Ray WA, Griffin MR, Fought RL, Adams ML. Identification of fractures from computerized medicare files. J Clin Epidemiol 1992;45:703-714.
22. Chan KA, Andrade SE, Boles M, et al. Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 2000;355:2185-2188. (Pubitemid 30394324)
23. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004;61:e59.
24. Robins JM, Gail MH, Lubin JH. More on "Biased selection of controls for case-control analyses of cohort studies". Biometrics 1986;42:293-299.
25. White SC, Atchison KA, Gornbein JA, Nattiv A, Paganini-Hill A, Service SK. Risk factors for fractures in older men and women: The Leisure World Cohort Study. Gend Med 2006;3:110-123. (Pubitemid 44069478)
26. Robinson K, Dennison A, Roalf D, et al. Falling risk factors in Parkinson's disease. NeuroRehabilitation 2005;20:169-182. (Pubitemid 43086575)
27. Sambrook P, Cooper C. Osteoporosis. Lancet 2006;367:2010-2018.
28. Liu B, Anderson G, Mittmann N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998;351:1303. (Pubitemid 28195906)
29. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-340. (Pubitemid 32107641)
30. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001;158:892-898. (Pubitemid 32547618)
31. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol 1993;46:1075-1079; discussion 1081-1090.
32. Rothman KJ, Greenland S. Modern epidemiology, 2nd ed. Philadelphia, PA: Lippincott-Raven; 1998.
33. FDA prescribing information for Seroquel (Rev Oct., 2007). Retrieved 11/13/2007 from http://www.astrazeneca-us.com/pi/seroquel.pdf.
34. Schneeweiss S, Glynn RJ, Avorn J, Solomon DH. A medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. J Clin Epidemiol 2005;58:98-102. (Pubitemid 40093118)
35. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
36. Ashburn A, Stack E, Pickering RM, Ward CD. A community-dwelling sample of people with Parkinson's disease: characteristics of fallers and non-fallers. Age Ageing 2001;30:47-52. (Pubitemid 32288234)
37. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005;172:1703-1711. (Pubitemid 40896865)
38. Deuschl G, Vaitkus A, Gabriele-Cornelia F, et al. Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. Mov Disord 2007;22:1550-1555. (Pubitemid 47477914)
39. Souverein PC, Webb DJ, Weil JG, Van Staa TP, Egberts AC. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006;66:1318-1324. (Pubitemid 43739637)
40. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-262. (Pubitemid 34126903)
41. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999;28:99-102. (Pubitemid 29161211)
42. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant LE. The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 2000;53:1248-1257. (Pubitemid 32007841)
43. Gill SS, Bronskill SE, Normand S-LT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146:775-786. (Pubitemid 351650498)